Prometheus Biosciences (RXDX) Financials

$199.92

$0.00 (0.00%)

As on 16-Jun-2023 09:30EDT

Market cap

$9,559 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

--

P/B Ratio

19.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	4.00	6.81	3.13	1.23	1.12	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	4.00	6.81	3.13	1.23	1.12	--
Operating Expenses	166.38	152.59	90.93	30.24	17.09	--
Operating Profit (EBIT)	-154.79	-145.78	-87.80	-29.01	-15.97	--
Other Income	9.26	--	-1.53	--	--	--
Profit before Tax	-150.56	-141.75	-90.20	-31.14	-16.73	--
Provision for Tax	-11.68	-4.66	1.27	6.00	12.99	0.00
Profit after Tax (Net Income)	-138.88	-137.10	-91.47	-37.14	-29.72	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-111.80	--	-90.20	-37.14	-29.72	-6.80

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	697.62	675.97	235.16	-97.54	-36.97	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	41.46	41.99	16.20	141.92	55.58	--
Current Liabilities	19.34	22.82	16.44	15.26	31.88	1.25
Total Liabilities	793.23	740.77	267.80	59.63	50.48	--

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	32.01	32.62	2.42	2.18	12.95	--
Current Assets	726.40	708.15	265.38	57.46	37.53	11.03
Total Assets	777.75	740.77	267.80	59.63	50.48	--
Total Debt*	29.46	29.54	--	7.40	--	--
Net Current Assets	707.06	685.33	248.94	42.20	5.66	--

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-123.25	-63.51	-28.02	-20.20	-6.10
Cash Flow from Investing Activities	--	--	-1.14	-1.06	7.93	-0.08
Cash from Financing Activities	--	562.20	267.69	79.89	9.76	10.14
Net Cash Inflow / Outflow	--	--	203.05	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-3.33	-3.34	-2.95	-37.14	--	--
Cash EPS ($)	--	-3.33	-2.94	-37.03	--	--
Adjusted Book Value ($)	--	16.49	7.59	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-3.01	-2.05	-28.02	--	--
Free Cash Flow per Share ($)	--	-3.07	-2.09	-28.22	--	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-29.15	-126.15	58.43	160.80	--
ROE (%)	-29.86	-30.09	-132.93	55.22	80.40	--
ROA (%)	-26.49	-27.19	-55.87	-67.45	-58.88	--
EBIT Margin (%)	-3,810.36	-2,140.96	-2,806.10	-2,360.21	-1,428.26	--
Net Margin (%)	-1,047.98	-2,013.47	-5,723.90	-3,021.81	-2,658.59	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	-36.47	1.18	1.55	0.10	--	--
EBIT Growth (%)	-40.73	-66.03	-202.70	-81.66	-134.86	--
Net Profit Growth (%)	-26.27	-49.89	-146.29	-24.95	--	--
EPS Growth (%)	-9.80	-0.13	0.92	--	--	--
Book Value Growth (%)	180.02	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-32.90	-13.40	--	--	--
Price / Book Value	19.88	6.67	5.21	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-33.16	-26.37	--	--	--	--
Close Price ($)	107.32	110.00	39.54	--	--	--
High Price ($)	129.60	117.73	39.98	--	--	--
Low Price ($)	21.50	21.50	16.11	--	--	--
Market Cap ($ Cr)	9,558.51	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	0.04	--	-0.08	--	--
Short term debt to equity ratio	0.00	0.00	0.05	-0.13	-0.20	--
Current Ratio	37.56	31.04	16.14	3.77	1.18	8.86
Quick Ratio	37.56	31.08	16.21	--	--	--
Interest Coverage	-73.79	-31.32	-101.98	-13.62	-20.74	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	15.11	34.48	88.36	--	--
Asset Turnover	0.01	0.01	0.02	0.02	0.02	--
Receivable days	--	56.54	126.36	161.38	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.